Voices of Alzheimer's urgently addresses the proposed reimbursement rates by CMS for critical Alzheimer’s diagnostic tools, particularly blood tests. These low reimbursement rates threaten to disincentivize laboratories and manufacturers from offering or investing in these critical tests, which are vital for early detection of Alzheimer’s disease. Early diagnosis is essential for the effectiveness of the first-ever disease-modifying treatments (DMTs), as they work best when the disease is identified at its onset. By undervaluing these tests, CMS limits patient access and stifles innovation in Alzheimer’s care, jeopardizing the health and quality of life for millions of Medicare beneficiaries.

This decision reflects a troubling pattern of inadequate support for the Alzheimer’s community, as CMS fails to recognize the disease as a significant national health crisis. A more comprehensive strategy is needed—one that prioritizes innovation, equity, and access, especially for underserved populations. The proposed reimbursement rates risk worsening existing health disparities, leaving vulnerable patients without necessary diagnostic and therapeutic options.

To advocate for a fairer reimbursement approach, Voices of Alzheimer’s has written a letter to Sarah Shirey-Losso, Director of Ambulatory Services at CMS. We invite you to sign our letter by October 24, 2024, to strengthen our message and join our collective effort for improved care and support for those affected by Alzheimer’s disease.